Schizophrenia is a serious mental illness that requires continuous and effective long-term
management to reduce symptoms, improve quality of life, and prevent relapse. Oral …

Aim Long‐acting injectable antipsychotic drugs (LAIs) are often used as an alternative to
oral antipsychotics (OAPs) in individuals with psychosis who demonstrate poor medication …

Objective: This study compared relapse prevention and acceptability of long-acting
injectable (LAI) antipsychotics in the maintenance treatment of adults with nonaffective …

Background This double-blind (DB), randomized, parallel-group study was designed to
evaluate efficacy and safety of paliperidone palmitate 6-month (PP6M) formulation relative to …

Medication nonadherence in schizophrenia can have serious implications including
relapses and hospitalization. Long-acting injectable (LAI) antipsychotics require fewer …

Objective: Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting
injectable antipsychotic formulation for administration every 2 months. A randomized, open …

Background The 3 paliperidone palmitate (PP) long-acting injectable antipsychotic
formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M), have …

We hypothesized that shifting from oral second-generation antipsychotics (SGA) to their long-
acting injectable (LAI) counterpart would be beneficial for the psychopathological, cognitive …

Introduction Poor adherence to antipsychotic medication is common in the treatment of
schizophrenia and other psychotic disorders. Paliperidone palmitate 3-monthly (PP3M) is …

Most patients with schizophrenia need life-long treatment. There is therefore a continued
need for effective and tolerable treatment options. A 2-monthly LAI formulation of …